Alphabet's GV Leads Funding in Gene Editing Company Verve Therapeutics

GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Comments

Popular posts from this blog

Garmin Instinct Crossover Solar With Up to 70 Days of Battery Life Launched in India: All Details

India’s Upcoming Digital Personal Data Protection Bill: Ten Things to Know About the Proposed Legislation